1. Alogliptin Attenuates Lipopolysaccharide-Induced Neuroinflammation in Mice Through Modulation of TLR4/MYD88/NF-κB and miRNA-155/SOCS-1 Signaling Pathways.
- Author
-
El-Sahar AE, Shiha NA, El Sayed NS, and Ahmed LA
- Subjects
- Animals, Behavior, Animal drug effects, Cognitive Dysfunction chemically induced, Disease Models, Animal, Lipopolysaccharides pharmacology, Male, Mice, Neuroinflammatory Diseases chemically induced, Signal Transduction drug effects, Uracil pharmacology, NF-kappaB-Inducing Kinase, Cognitive Dysfunction drug therapy, Dipeptidyl-Peptidase IV Inhibitors pharmacology, MicroRNAs drug effects, Myeloid Differentiation Factor 88 drug effects, Neuroinflammatory Diseases drug therapy, Neuroprotective Agents pharmacology, Piperidines pharmacology, Protein Serine-Threonine Kinases drug effects, Suppressor of Cytokine Signaling 1 Protein drug effects, Toll-Like Receptor 4 drug effects, Uracil analogs & derivatives
- Abstract
Background: Endotoxin-induced neuroinflammation plays a crucial role in the pathogenesis and progression of various neurodegenerative diseases. A growing body of evidence supports that incretin-acting drugs possess various neuroprotective effects that can improve learning and memory impairments in Alzheimer's disease models. Thus, the present study aimed to investigate whether alogliptin, a dipeptidyl peptidase-4 inhibitor, has neuroprotective effects against lipopolysaccharide (LPS)-induced neuroinflammation and cognitive impairment in mice as well as the potential mechanisms underlying these effects., Methods: Mice were treated with alogliptin (20 mg/kg/d; p.o.) for 14 days, starting 1 day prior to intracerebroventricular LPS injection (8 μg/μL in 3 μL)., Results: Alogliptin treatment alleviated LPS-induced cognitive impairment as assessed by Morris water maze and novel object recognition tests. Moreover, alogliptin reversed LPS-induced increases in toll-like receptor 4 and myeloid differentiation primary response 88 protein expression, nuclear factor-κB p65 content, and microRNA-155 gene expression. It also rescued LPS-induced decreases in suppressor of cytokine signaling gene expression, cyclic adenosine monophosphate (cAMP) content, and phosphorylated cAMP response element binding protein expression in the brain., Conclusion: The present study sheds light on the potential neuroprotective effects of alogliptin against intracerebroventricular LPS-induced neuroinflammation and its associated memory impairment via inhibition of toll-like receptor 4/ myeloid differentiation primary response 88/ nuclear factor-κB signaling, modulation of microRNA-155/suppressor of cytokine signaling-1 expression, and enhancement of cAMP/phosphorylated cAMP response element binding protein signaling., (© The Author(s) 2020. Published by Oxford University Press on behalf of CINP.)
- Published
- 2021
- Full Text
- View/download PDF